ERBB2 and cancer: In particular, increased BRIP1 transcript levels were found in tumors with an estrogen receptor-negative, progesterone receptor-negative or HER-2-positive status, in basal-like cancers and in stage 2 tumors as compared to stage 1 carcinomas.